| Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton M Krendel, FT Zenke, GM Bokoch Nature cell biology 4 (4), 294-301, 2002 | 757 | 2002 |
| Nitric oxide destroys zinc-sulfur clusters inducing zinc release from metallothionein and inhibition of the zinc finger-type yeast transcription activator LAC9 KD Kroncke, K Fehsel, T Schmidt, FT Zenke, I Dasting, JR Wesener, ... Biochemical and biophysical research communications 200 (2), 1105-1110, 1994 | 362 | 1994 |
| Identification of a central phosphorylation site in p21-activated kinase regulating autoinhibition and kinase activity FT Zenke, CC King, BP Bohl, GM Bokoch Journal of Biological Chemistry 274 (46), 32565-32573, 1999 | 307 | 1999 |
| p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1) CC King, EMM Gardiner, FT Zenke, BP Bohl, AC Newton, BA Hemmings, ... Journal of Biological Chemistry 275 (52), 41201-41209, 2000 | 291 | 2000 |
| p21-activated kinase 1 phosphorylates and regulates 14-3-3 binding to GEF-H1, a microtubule-localized Rho exchange factor FT Zenke, M Krendel, C DerMardirossian, CC King, BP Bohl, GM Bokoch Journal of Biological Chemistry 279 (18), 18392-18400, 2004 | 203 | 2004 |
| Activation of Gal4p by galactose-dependent interaction of galactokinase and Gal80p FT Zenke, R Engels, V Vollenbroich, J Meyer, CP Hollenberg, KD Breunig Science 272 (5268), 1662-1665, 1996 | 187 | 1996 |
| αPix stimulates p21-activated kinase activity through exchange factor-dependent and-independent mechanisms RH Daniels, FT Zenke, GM Bokoch Journal of Biological Chemistry 274 (10), 6047-6050, 1999 | 176 | 1999 |
| Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate JD Orth, Y Tang, J Shi, CT Loy, C Amendt, C Wilm, FT Zenke, TJ Mitchison Molecular cancer therapeutics 7 (11), 3480-3489, 2008 | 134 | 2008 |
| Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1 CC King, FT Zenke, PE Dawson, EM Dutil, AC Newton, BA Hemmings, ... Journal of Biological Chemistry 275 (24), 18108-18113, 2000 | 133 | 2000 |
| Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress A Thomas, N Takahashi, VN Rajapakse, X Zhang, Y Sun, M Ceribelli, ... Cancer Cell 39 (4), 566-579. e7, 2021 | 126 | 2021 |
| Cutting edge: p21-activated kinase (PAK) is required for Fas-induced JNK activation in Jurkat cells T Rudel, FT Zenke, TH Chuang, GM Bokoch The Journal of Immunology 160 (1), 7-11, 1998 | 122 | 1998 |
| Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models FT Zenke, A Zimmermann, C Sirrenberg, H Dahmen, V Kirkin, U Pehl, ... Molecular cancer therapeutics 19 (5), 1091-1101, 2020 | 111 | 2020 |
| Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation C Klein, I Dokic, A Mairani, S Mein, S Brons, P Häring, T Haberer, O Jäkel, ... Radiation Oncology 12, 1-8, 2017 | 97 | 2017 |
| Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents U Jo, IS Senatorov, A Zimmermann, LK Saha, Y Murai, SH Kim, ... Molecular cancer therapeutics 20 (8), 1431-1441, 2021 | 73 | 2021 |
| The discovery and optimization of hexahydro-2H-pyrano [3, 2-c] quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 K Schiemann, D Finsinger, F Zenke, C Amendt, T Knöchel, D Bruge, ... Bioorganic & medicinal chemistry letters 20 (5), 1491-1495, 2010 | 69 | 2010 |
| Gal80 Proteins of Kluyveromyces lactis and Saccharomyces cerevisiae Are Highly Conserved but Contribute Differently to Glucose Repression of the Galactose … FT Zenke, W Zachariae, A Lunkes, KD Breunig Molecular and cellular biology 13 (12), 7566-7576, 1993 | 67 | 1993 |
| Morpholinylquinazolines W Mederski, T Fuchss, F Zenke US Patent 9,126,952, 2015 | 65 | 2015 |
| Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814 Q Sun, Y Guo, X Liu, F Czauderna, MI Carr, FT Zenke, A Blaukat, ... Molecular Cancer Research 17 (12), 2457-2468, 2019 | 60 | 2019 |
| Pyridinamide derivatives as kinase inhibitors L Burgdorf, HP Buchstaller, F Stieber, C Amendt, H Greiner, M Grell, ... US Patent App. 10/590,724, 2007 | 48 | 2007 |
| Tetrahydrobenzoisoxazole and tetrahydroindazole derivatives as modulators of the mitotic motor protein K Schiemann, D Finsinger, F Zenke US Patent App. 12/520,451, 2010 | 47 | 2010 |
Lyubomir (Lubo) VassilevEMD Serono Research & Development Institute, Inc.Verified email at emdserono.com
